These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33650272)

  • 1. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
    Agbo F; Crass RL; Chiu YY; Chapel S; Galluppi G; Blum D; Navia B
    Clin Transl Sci; 2021 Jul; 14(4):1464-1475. PubMed ID: 33650272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients.
    Thijssen E; Tuk B; Cakici M; van Velze V; Klaassen E; Merkus F; van Laar T; Kremer P; Groeneveld GJ
    Clin Transl Sci; 2024 May; 17(5):e13796. PubMed ID: 38712716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
    Nasser A; Gomeni R; Ceresoli-Borroni G; Xie L; Busse GD; Melyan Z; Rubin J
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):385-393. PubMed ID: 38578533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
    van Laar T; Neef C; Danhof M; Roon KI; Roos RA
    Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study.
    Agbo F; Isaacson SH; Gil R; Chiu YY; Brantley SJ; Bhargava P; Navia B
    Neurol Ther; 2021 Dec; 10(2):693-709. PubMed ID: 33991326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
    Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
    Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
    J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
    Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
    Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.
    Sam E; Jeanjean AP; Maloteaux JM; Verbeke N
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):27-33. PubMed ID: 7588990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
    LeWitt PA
    Neurology; 2004 Mar; 62(6 Suppl 4):S8-11. PubMed ID: 15037665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
    Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
    J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
    Montastruc JL; Rascol O; Senard JM; Gualano V; Bagheri H; Houin G; Lees A; Rascol A
    Clin Neuropharmacol; 1991 Oct; 14(5):432-7. PubMed ID: 1742752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient.
    Junginger HE
    Adv Drug Deliv Rev; 2002 Nov; 54 Suppl 1():S57-75. PubMed ID: 12460716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
    Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
    J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
    Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
    Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
    van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
    Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual apomorphine in the treatment of Parkinson's disease.
    Kassubek J; Jost WH; Schwarz J
    J Neural Transm (Vienna); 2024 Oct; 131(10):1209-1216. PubMed ID: 38743091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.